SCHEMBL2950323

SCHEMBL2950323

COCCOCCCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
TSHR P16473 7/20 0.50
LMNA P02545 2/20 0.43
SLC22A6 Q4U2R8 2/20 0.43
NFKB1 P19838 1/20 0.42
PMP22 Q01453 1/20 0.42
AKR1B1 P15121 1/20 0.41
GPR84 Q9NQS5 7/20 0.39
PPARG P37231 6/20 0.39
PPARD Q03181 6/20 0.39
PPARA Q07869 6/20 0.39
HDAC11 Q96DB2 5/20 0.39
TLR2 O60603 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FABP4 P15090 2/20 0.39
PTPN1 P18031 2/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
MEN1 O00255 1/20 0.39
ESR1 P03372 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL915377 1.00 ALDH1A1 (0.61) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL21876923 1.00 ALDH1A1 (0.61) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL17908913 1.00 ALDH1A1 (0.61) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL29016026 1.00 ALDH1A1 (0.61) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL23191004 0.93 ALDH1A1 (0.72) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL30008420 0.93 ALDH1A1 (0.72) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL5355625 0.93 ALDH1A1 (0.72) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL30008592 0.93 ALDH1A1 (0.72) ALDH1A1TSHRLMNASLC22A6NFKB1
SCHEMBL5351480 0.93 ALDH1A1 (0.72) ALDH1A1TSHRLMNASLC22A6NFKB1
Adipic Acid SCHEMBL4805967 0.93 ALDH1A1 (0.71) ALDH1A1TSHRLMNASLC22A6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651698-B1 ISOCYANATE-FREE PRIMER COMPOSITION FOR GLASS AND GLASS CERAMICS SIKA TECHNOLOGY AG (CH) 2012-09-12 EP claimed
EP-1651698-A1 ISOCYANATE-FREE PRIMER COMPOSITION FOR GLASS AND GLASS CERAMICS Sika Technology AG (CH) 2006-05-03 EP claimed
WO-2005012382-A1 ISOCYANATE-FREE PRIMER COMPOSITION FOR GLASS AND GLASS CERAMICS SIKA TECHNOLOGY AG (CH) 2005-02-10 WO claimed
EP-1502927-A1 Isocyanate free primer composition for glass and glass-ceramics Sika Technology AG (CH) 2005-02-02 EP claimed
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
CN-115702234-A Environment-friendly solvent, and washing composition and washing device comprising same 株式会社LG生活健康 2023-02-14 CN disclosed
US-20220185785-A1 INHIBITORS OF CD40-CD154 BINDING TONIX Pharmaceuticals Holding Corp (US) 2022-06-16 US disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed
EP-3952853-A1 INHIBITORS OF CD40-CD154 BINDING Tonix Pharmaceuticals Holding Corp. (US) 2022-02-16 EP disclosed
WO-2020210831-A1 INHIBITORS OF CD40-CD154 BINDING TONIX Pharmaceuticals Holding Corp (US) 2020-10-15 WO disclosed
EP-3048093-B1 ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF MORESCO CORP (JP) 2019-02-20 EP disclosed
US-20080318018-A1 Black Resin Composition for Display Device, and Member for Display Device DAI NIPPON PRINTING CO., LTD. (JP) 2008-12-25 US disclosed
WO-2008133896-A2 DUAL-ACTING ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2008-11-06 WO disclosed
US-20070043196-A1 Isocyanate-free primer composition for glass and glass ceramics SIKA TECHNOLOGY AG (CH) 2007-02-22 US disclosed
EP-1502927-A1 Isocyanate free primer composition for glass and glass-ceramics Sika Technology AG (CH) 2005-02-02 EP disclosed
EP-0950078-B1 PERFLUOROETHER-CONTAINING FLUOROELASTOMERS WITH GOOD LOW TEMPERATURE CHARACTERISTICS DYNEON LLC (US) 2001-10-10 EP disclosed
EP-0950078-A1 PERFLUOROETHER-CONTAINING FLUOROELASTOMERS WITH GOOD LOW TEMPERATURE CHARACTERISTICS DYNEON LLC (US) 1999-10-20 EP disclosed
US-5891965-A CURABLE COMPOSITION DYNEON LLC (US) 1999-04-06 US disclosed
WO-1998030631-A1 PERFLUOROETHER-CONTAINING FLUOROELASTOMERS WITH GOOD LOW TEMPERATURE CHARACTERISTICS DYNEON LLC (US) 1998-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185785-A1 INHIBITORS OF CD40-CD154 BINDING CD40LG, CD40, CD4 ALDH1A1 1606/4885TSHR 908/4885LMNA 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.